Annual Report

Overview

The report records 2025 revenue of RMB177,255 thousand from LBL-047 licensing payments. The company continued expanding LBL-024 development across solid-tumor indications and completed enrollment of its pivotal EP-NEC trial. It also entered an exclusive global LBL-047 license with Dianthus and had received US$30 million in aggregate payments by the report date. The Group had 244 full-time employees at year-end.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: Ends 31 December 2025
Publication date: 27 March 2026
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services